Lupin

History

Year	Detail
1968	Dr. Desh Bandhu Gupta founded Lupin by borrowing $60.4 from his wife. He then set up its first manufacturing plant, which supplied the government of India with iron and folic acid tablets.
1979	Lupin commissioned its first formulations plant and R&D Centre at Aurangabad, India.
1988	Dr. Desh Bandhu Gupta laid the foundation of the Lupin Human Welfare and Research Foundation (LHWRF), which has been working for the upliftment of underprivileged communities through social development initiatives in India.
1989	Lupin Chemicals (Thailand) Ltd. was established through a J.V. in Thailand and received U.S. FDA approvals for the Ankleshwar and Mandideep plants.
1992	The company established a Fermentation Plant of Lupin Chemicals Ltd. Tarapur, Maharashtra.
2003	Lupin Pharmaceuticals Inc. USA was established for trading, marketing, and developmental activities in the U.S.
2008	The company expanded its product portfolio in Japan-Kyowa by receiving approval for ten products from the Ministry of Health and Labour Welfare in Japan.
	The company acquired Hormosan Pharma GmbH (Hormosan), a German sales and marketing generics company specializing in the supply of pharmaceutical products for the Central Nervous System (CNS).
	The company has expanded its business by acquiring a majority 60% equity stake in Pharma Dynamics, South Africa.
2011	Lupin entered a research and development agreement with Medicis Pharmaceutical Corp. to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.
2014	The company entered the Latin American market by acquiring Laboratorios Grin S.A. De C.V., a specialty ophthalmic company in Mexico.
	Lupin entered into a strategic joint venture agreement with Yoshindo Inc., a Japanese pharmaceutical company, to develop a new entity, Y.L. Biologics (YLB).
2015	The company entered into an asset purchase agreement with Temmler Pharma GMBH and CO. K.G. to acquire its specialty product portfolio.
2017	Lupin, Inc. acquired Symbiomix Therapeutics, LLC, for a cash consideration of $150 million, including a $50 million upfront payment and other time-based payments.
2019	Lupin inked a pact with Boehringer Ingelheim for the clinical development of MEK inhibitors to treat difficult-to-treat cancers.
2020	Lupin and Mylan N.V. collaborated to launch Nepexto, a biosimilar etanercept, in the German market. Nepexto is used to treat moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis, and chronic severe plaque psoriasis in children and adolescents.
2021	The company launched its diagnostics business as part of its strategy to provide integrated healthcare in India.
2022	Lupin has signed an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol, from Sunovion Pharmaceuticals Inc. for a worth of $75.1 million.
2023	Lupin Launched a fixed-dose triple drug combination, DIFIZMA DPI, to treat inadequately controlled asthma.
	Lupin Launched its first fixed-dose triple combination drug, Vilfuro-G, for COPD Management in India.
2024	Lupin acquired nine brands such as AntaGolin, RyChol, NeuroVance, SkinVance, FlamLeve, Rheumalin, SleepVance, ImmunoVance, and OviVance of Medical Nutritional Institute in South Africa.